gamma-Valerolactone | CAS:108-29-2
gamma-Valerolactone
- 名称：gamma-戊内酯; 丙位戊内酯 | gamma-Valerolactone
- CAS号：108-29-2
- 别名：4,5-Dihydro-5-methyl-2(3H)-furanone; 4-Hydroxypentanoic acid lactone
- 分子式：C5H8O2
- 分子量：100.12
- EINESC号：203-569-5
产品描述
物理化学性质
| 熔点 | -31 ºC |
|---|---|
| 水溶性 | MISCIBLE |
| 沸点 | 207-208 ºC |
| 闪点 | 96 ºC |
| 密度 | 1.05 |
| 折射率 | 1.432-1.434 |
安全数据
| 危险品标志 | Xi |
|---|---|
| 危险类别码 | R36 |
| 安全说明书 | S26;S39 |
SDS
| 来源 | SDS样本 |
|---|---|
| 没有数据 | 没有数据 |
产品合成路线
| 名称 | CAS号 |
|---|
更多
文章
同行评议文献
Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate.Toni M Brand et al.Cancer biology & therapy, 11(3), 368-370 (2011-01-14)
Lithium citrate for Canavan disease.Christopher G Janson et al.Pediatric neurology, 33(4), 235-243 (2005-10-01)
Quantification of physiological amino acids by gradient ion-exchange high-performance liquid chromatography.S E Møller Journal of chromatography, 613(2), 223-230 (1993-04-02)
Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease.Assadi M, Janson C, Wang DJ, et al. European Journal of Pediatrics, 14, 354-359 (2010)
Lithium citrate as treatment of Canavan disease.María Dolores Edo Solsona et al.Clinical neuropharmacology, 35(3), 150-151 (2012-05-18)
备注
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1).
| 名称 | CAS号 |
|---|
相关产品
相关资讯
问
热门标签
询 单
请 填 写 相 关 信 息
- 请填写产品名称！
- CAS号
- 请正确填写公司名称！
- 请正确填写联系人！
- 请正确填写联系电话！
- 请正确填写联系邮箱！
- 请描述您的问题！